FDA Reopens Comment Period on Title 21 Terminology Rule

FDA is giving the public sixty more days to weigh in on a rule that would strip the word “gender” out of Title 21 of the Code of Federal Regulations — the chapter that governs food, drugs, medical devices, biologics, and cosmetics. The proposed rule itself is not new; it first ran in the Federal Register on May 6, 2026. What is new is the reopened comment window, published August 3, which pushes the deadline to October 2 and gives regulatory and quality teams more time to check whether the specific cross-references they rely on are among the ones changing.

What the rule actually touches

Title 21 uses the word “gender” in scattered places — some substantive, most incidental to a regulation's real subject. FDA's proposal is a terminology sweep: wherever “gender” appears, the rule would swap in “sex” or drop the reference outright, whichever the surrounding text supports, alongside what the agency calls unrelated editorial changes to improve readability. FDA has not published a section-by-section list of every affected provision as part of this reopening notice; the underlying content of the May 6 proposed rule is what commenters are being asked to review.

Why a comment period reopens instead of just running longer

Federal rulemaking under the Administrative Procedure Act runs on notice-and-comment: an agency proposes a rule, the public gets a defined window to respond, and the agency has to consider those comments before finalizing anything. A reopening is procedurally distinct from an extension — it means the original window had already closed, and FDA elected to accept a fresh round of input rather than proceed straight to a final rule. The agency's stated reason here is to give interested persons additional time to submit comments; the notice does not describe the volume or content of comments received in the initial window.

• May 6, 2026 — the proposed rule, “Modification of Certain Terminology in Title 21,” first appears in the Federal Register.
• August 3, 2026 — FDA publishes a notice reopening the comment period for an additional 60 days.
• October 2, 2026 — the new deadline for comments to docket FDA-2026-N-2886.
• No date has been set for a final rule; FDA reviews comments before proceeding.

The operational question for compliance teams

A pure terminology rule rarely changes what a company has to do. It can still change what a company's documents say. SOPs, validation protocols, and labeling that quote or paraphrase specific CFR language — anything built on a section citation rather than a plain-English summary — are the parts of a quality system most likely to need a text update once a final rule lands, even when the underlying obligation is unchanged. That is a smaller lift than most Federal Register notices generate, but it is not zero, and the sixty extra days are the window to flag it before the text is locked. Comment-period mechanics like this one are also where FDA's public-input process becomes visible in practice, the same machinery FDA relies on to request public data before it moves on a rule.